Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AZD1446 · 3 trials · 3 indications
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | AZD1446 60mg once daily + donepezil 10mg |
| 2 | EXPERIMENTAL | AZD1446 60mg three times daily + donepezil 10mg |
| 3 | EXPERIMENTAL | AZD1446 30mg three times daily + donepezil 10mg |
| 4 | PLACEBO_COMPARATOR | placebo + donepezil 10mg |
| A | EXPERIMENTAL | Single dose of AZD1446 10 mg |
| B | EXPERIMENTAL | Single dose of AZD1446 80 mg |
| C | ACTIVE_COMPARATOR | Single Dose of Donepezil 5 mg |
| D | PLACEBO_COMPARATOR | Single dose of placebo to match AZD1446 |
| Name | Type | Description |
|---|---|---|
| AZD1446 | DRUG | capsules, oral, 3 times daily |
| Placebo | DRUG | capsules, oral, 3 times daily, 4 weeks |
| donepezil | DRUG | capsule, single oral dose |
Inclusion Criteria: * history of progressive worsening of memory and other cognitive functions for at least 12 months * treatment with stable dose of donepezil (10 mg) for at least 3 months * the patient should have an appropriate caregiver, who is required for all study visits Exclusion Criteria:...
AZD1446 is an investigational small molecule developed by AstraZeneca PLC (ticker AZN) for psychiatric and cognitive conditions. It has been studied in adult ADHD, cognition, and mild to moderate Alzheimer's disease. It is a Phase 2 candidate and has not been approved for any indication.
AZD1446 has been studied for adult ADHD, cognition, and mild to moderate Alzheimer's disease. It is an investigational drug and is not approved for any of these uses. Clinical testing has included a Phase 2 trial in adult ADHD and a Phase 2 trial in mild to moderate Alzheimer's disease.
AZD1446 targets CHRNB2 and CHRNA4, which are nicotinic acetylcholine receptor subunits. It acts as an agonist at these targets. This receptor activity is the basis for its investigation in ADHD and cognitive impairment, though it remains an investigational agent.
AZD1446 is developed by AstraZeneca PLC, which trades under the ticker AZN. AstraZeneca sponsored the clinical trials of AZD1446, including studies in adult ADHD, cognition, and mild to moderate Alzheimer's disease.
AZD1446 is in Phase 2 development. It has completed Phase 2 trials in adult ADHD and in mild to moderate Alzheimer's disease, as well as a Phase 1 cognition study. It is investigational and has not been approved by the FDA or any other regulatory agency.
AZD1446 has completed three trials: NCT01044342, a Phase 1 cognition study in healthy male volunteers in France; NCT01039701, a Phase 2 safety and tolerability study in mild to moderate Alzheimer's disease in Czechia, Hungary, and Slovakia; and NCT01012375, a Phase 2 efficacy and tolerability study in adult ADHD in the United States.